Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome

Expert Opinion on Drug Safety

Volumn 11, Issue 5, 2012, Pages 841-850

  Chamberlain, Sherman M ^a   Rao, Satish S C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

chronic idiopathic constipation; intestinal secretion; irritable bowel syndrome; lubiprostone

Indexed keywords

LUBIPROSTONE; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; BLOATING; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FLATULENCE; HEADACHE; HUMAN; IRRITABLE COLON; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; NAUSEA; REVIEW; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ADULT; ALPROSTADIL; ANIMALS; CHLORIDE CHANNELS; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INCIDENCE; IRRITABLE BOWEL SYNDROME; LAXATIVES; NAUSEA; PHARMACOVIGILANCE;

EID: 84865498099     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.708732     Document Type: Review

References (32)

1. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999;94:3530-40
2. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80 (Pubitemid 23271409)
3. Singh G, Lingala V, Wang H, et al. Use of health care resources and the cost of care for adults with constipation. Clin Gastroenterol Hepatol 2007; 5:1053-8
4. Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-93
5. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001; 96:3130-7 (Pubitemid 33095352)
6. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
7. Longstreth GF, Thompson WG, Chey WD, et al. In: Drossman DA, Corazziari E, Delvaux M, et al. editors. Rome III: the functional gastrointestinal disorders. 1st edition. Degnon Associates; McLean, VA: 2006. p. 487-555
8. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-7
9. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation; a double-blind placebo-controlled, dose ranging study to evaluate safety and efficacy. Aliment Pharmacol Ther 2007;25:1351-61 (Pubitemid 46763456)
10. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Phamacol 2008;154:126-35 (Pubitemid 351634400)
11. Jentsch TJ. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit Rev Biochem Mol Biol 2008; 43:3-36 (Pubitemid 351315859)
12. Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complimentary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011;5: 253-66
13. Moeser AJ, Haskell MM, Shifflett DE, et al. ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. Gastroenterology 2004; 127:802-15 (Pubitemid 39208413)
14. Moeser A, Nighot P, Roerig B, et al. Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine. World J Gastroenterol 2008;14:6012-17
15. Moeser AJ, Nighot PK, Engelke KJ, et al. Recovery of mucosal barrier function in ichemic porcine ileum and colon is stimulated by a novel agonist of the CID-2 chloride channel, lubiprostone. Am J Physiol Gastrointestinal Liver Physiol 2007;292:G647-56
16. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral drug delivery of lipophilic drugs. Biomed Phamacother 2004; 58:173-82 (Pubitemid 38479922)
17. Mizumori M, Akiba Y, Kaunitz JD. Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci 2009;54:2063-9
18. Amitiza (lubiprostone) package insert. Sucampo Pharmaceuticals, Inc; Bethesda, MD: 2009
19. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96 (Pubitemid 351406304)
20. Barish CF, Drossman D, Johanson J, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dig Sci 2010;55:1090-7
21. Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 2011;56:1619-25
22. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29: 329-41
23. Lembo A, Johanson J, Parkman H, et al. Long-Term safety and effectiveness of lubiprostone, a chloride channel (CID-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011;56:2639-45
24. Fokudo S, Hongo M, Kaneko H, et al. Efficacy and safty of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011;23:544-e205
25. Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99
26. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008;154:126-35 (Pubitemid 351634400)
27. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007;19:545-52 (Pubitemid 46985594)
28. FDA Center for Drug Evaluation and Research (CDER)-2008
29. Lisle R, Mueller R, Roach E. Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype. BMC Gastroenterol 2010;10:107
30. MacDonald K, McKenzie K, Henderson M, et al. Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol 2008;295:L933-40
31. Kapoor S. Lubiprostone: clinical applications beyond constipation. World J Gastroenterol 2009; 15(9):1147
32. Lackner J, Jaccard J, Baum C, et al. Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors. Clin Gastroenterol Hepatol 2011;9:957-64